Pfizer Faces Antitrust Suit Over Generic Lipitor Delay
A group of health and welfare benefit plans launched a putative class action Monday in New York accusing Pfizer Inc. of filing sham patent applications and of colluding with Ranbaxy Inc....To view the full article, register now.
Already a subscriber? Click here to view full article